ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Synthesis

Natural Product Precursor Could Hit Cancer Selectively

Drug Discovery: Leinamycin E1’s cytotoxic mechanism is selective for cancer cells

by Stu Borman
June 22, 2015 | APPEARED IN VOLUME 93, ISSUE 25

Researchers have isolated and characterized a precursor of the anticancer agent leinamycin that could have more highly selective anticancer activity and fewer side effects than leinamycin itself. Leinamycin is a natural product that, in the presence of cellular thiols, forms an episulfonium ion that alkylates DNA, causing DNA cleavage and cell death. But it can kill cancer cells and normal cells, likely contributing to its substantial toxicity. Ben Shen of Scripps Research Institute Florida and coworkers have now manipulated the leinamycin biosynthetic pathway to make engineered bacteria produce a precursor, leinamycin E1 (Proc. Natl. Acad. Sci. USA 2015, DOI: 10.1073/pnas.1506761112). E1 also forms an episulfonium ion that alkylates DNA, but it does so in the presence of reactive oxygen species (ROS) instead of thiols. Cancer cells are under higher oxidative stress and have higher levels of ROS than normal cells do, so E1 acts as an ROS-activated prodrug that would likely be selective for cancer cells. Shen and his coworkers are currently looking for analogs of leinamycin E1 with the same mechanism for potential development as anticancer agents.

09325-scicon-leinamycin-690.jpg
Leinamycin E1 (left) kills cancer cells by alkylating DNA in the presence of reactive oxygen species.
X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment